GSK scales back breast cancer trial
September 12, 2011Research and Development, Sales and Marketing GSK, Tyverb
GSK has halted one of the four phase III studies that make up the ALTTO programme for its cancer drug …
Takeda moves potential first-in-class diabetes drug into phase III
September 12, 2011Research and Development, Sales and Marketing TAK-875, Takeda, diabetes
Takeda has moved its potential first-in-class diabetes candidate TAK-875 into phase III clinical trials. The company hopes TAK-875 will offer …
Digital Pharma: Twitter slip-up shouldn’t silence pharma
September 9, 2011Medical Communications, Sales and Marketing Bayer, Code of Practice, Digital Pharma blog, PMCPA, Twitter
Bayer UK was recently ruled to have breached the ABPI Code of Practice by promoting prescription-only medicines to the general …
Pan appoints trio of new starters
September 9, 2011Medical Communications appointment, medical communications
Pan Advertising has appointed a trio of new starters across its creative and client services teams. Maneesh Sharma joins the …
Branding agency 1HQ appoints Burton Paul
September 9, 2011Medical Communications appointment, medical communications
Burton Paul has joined Windsor, UK-based branding agency 1HQ as client director to head up their health division. He has …
EMA grants first paediatric use marketing authorisation
September 9, 2011Sales and Marketing Buccolam, PUMA, Viropharma, paediatric trials, seizures
The first children’s medicine to hold a new paediatric use marketing authorisation (PUMA), making it available for children only, has …
European approval for prostate cancer drug Zytiga
September 8, 2011Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer
Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
Everolimus approved to treat rare tumour disease
September 8, 2011Sales and Marketing Novartis, SEGA, Votubia, everolimus
Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
New ABPI chief executive to focus on industry reputation
September 8, 2011Research and Development, Sales and Marketing ABPI, industry relations
The new chief executive of the ABPI used his first public speech to focus on the reputation of the pharma …
Sanofi banks on personalised medicine for growth
September 8, 2011Sales and Marketing Genzyme, Sanofi
Sanofi has nailed its colours to the mast of personalised medicine, banking on the purchase of US biotech company Genzyme, …
Algeta appoints first head of comms and investor relations
September 8, 2011Medical Communications, Research and Development appointment, medical communications, research and development
Norwegian biotech Algeta has appointed Dr Mike Booth to the newly-created role of senior VP of communications and corporate affairs. …
Dendreon drops GSK as Provenge manufacturing partner
September 8, 2011Manufacturing and Production Dendreon, GSK, Provenge, pharma manufacturing news
Dendreon has called a halt to its manufacturing and supply deal with GlaxoSmithKline for cancer vaccine Provenge, citing “delays and …
Forecasting future launch success
September 8, 2011Sales and Marketing Champix, Enbrel, forecast planning, forecasting
Pharmaceutical companies are moving into new and sometimes very different (often specialised) therapy areas, because of global market conditions and …
Clinical research news in brief
September 8, 2011Research and Development research and development news
This roundup includes using social media to recruit trial subjects, a strategic level service deal between BMS and Icon, plus …
Eisai shares risk with novel trial funding approach
September 7, 2011Research and Development Eisai, clinical trials, research and development news
Eisai has unveiled a novel risk-sharing approach to accelerate its late-stage research programme by accepting new sources of clinical trial …
Battle over health reform begins again
September 7, 2011Health and Social Care Bill, NHS, NHS reforms
The battle over the future of the NHS has began again as the Health and Social Care Bill yesterday returned …
NICE recommends Takeda’s cancer drug Mepact
September 7, 2011Sales and Marketing Mepact, NICE, Takeda
NICE has reversed its stance on Mepact and recommended the bone cancer drug after re-examining discounts and a new patient …
EMA should compare ‘like-for-like’ when assessing new drugs
September 7, 2011Research and Development EMA, clnical trials, research and development news
The European system of comparing drugs against placebo and not against a comparator is flawed, according to a new LSE …
Sanofi’s Multaq in the dock
September 7, 2011Sales and Marketing Multaq, Sanofi
The EMA will later this month decide whether Sanofi’s Multaq can remain on the market after reports emerged of serious …
AZ’s Nexium faces generic competition in the UK
September 6, 2011Nexium, Ranbaxy, generics
Generic specialist Ranbaxy has launched its version of AstraZeneca’s anti-ulcer blockbuster Nexium in the UK. It will be available in …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
